Incyte (INCY) Tops Q4 EPS by 32c
Incyte (NASDAQ: INCY) reported Q4 EPS of $0.62, $0.32 better than the analyst estimate of $0.30. Revenue for the quarter came in at $926.7 million versus the consensus estimate of $878.16 million.
2023 Financial Guidance
Guidance does not include revenue from any potential new product launches or the impact of any potential future strategic transactions. Incyte’s guidance is summarized below.
| Current |
Jakafi net product revenues | $2.53 - $2.63 billion |
Other Hematology/Oncology net product revenues(1) | $215 - $225 million |
GAAP Cost of product revenues | 7 – 8% of net product revenues |
Non-GAAP Cost of product revenues(2) | 6 – 7% of net product revenues |
GAAP Research and development expenses  | $1,610 - $1,650 million |
Non-GAAP Research and development expenses(3) | $1,485 - $1,520 million |
GAAP Selling, general and administrative expenses | $1,050 - $1,150 million |
Non-GAAP Selling, general and administrative expenses(3) | $965 - $1,060 million |
1 | Pemazyre in the U.S., EU and Japan and Iclusig and Minjuvi in the EU. |
2 | Adjusted to exclude the amortization of licensed intellectual property for Iclusig relating to the acquisition of the European business of ARIAD Pharmaceuticals, Inc. and the estimated cost of stock-based compensation. |
3 | Adjusted to exclude the estimated cost of stock-based compensation. |
For earnings history and earnings-related data on Incyte (INCY) click here.